These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 21240643)

  • 1. Bioanalytical approaches to quantify "total" and "free" therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development.
    Lee JW; Kelley M; King LE; Yang J; Salimi-Moosavi H; Tang MT; Lu JF; Kamerud J; Ahene A; Myler H; Rogers C
    AAPS J; 2011 Mar; 13(1):99-110. PubMed ID: 21240643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Shed/Soluble targets on the PK/PD of approved therapeutic monoclonal antibodies.
    Samineni D; Girish S; Li C
    Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1557-1569. PubMed ID: 27766899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Automated Bioanalytical Workflow for Ligand Binding-Based Pharmacokinetic Assay Development.
    Evans BR; Beck AG; Yeung L; Li A; Lee DH; Bateman KP; Chopra G
    Anal Chem; 2024 Jan; 96(1):488-495. PubMed ID: 38156369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical role of bioanalytical strategies in investigation of clinical PK observations, a Phase I case study.
    Peng K; Xu K; Liu L; Hendricks R; Delarosa R; Erickson R; Budha N; Leabman M; Song A; Kaur S; Fischer SK
    MAbs; 2014; 6(6):1500-8. PubMed ID: 25484037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel immunoassay to measure total serum lymphotoxin-α levels in the presence of an anti-LTα therapeutic antibody.
    Young J; Nguyen A; Qiu ZJ; Ying Y; Gao X; Reed C; Chuntharapai A; Deng R; Lutman J; Grogan J; Wong WL; DeForge L
    J Immunol Methods; 2015 Sep; 424():91-9. PubMed ID: 26009247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic monoclonal antibody concentration monitoring: free or total?
    Kuang B; King L; Wang HF
    Bioanalysis; 2010 Jun; 2(6):1125-40. PubMed ID: 21083212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
    Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
    Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of Antibody-Drug Conjugate Pharmacokinetics and in Vivo Biotransformation Using Quantitative Intact LC-HRMS and Surrogate Analyte LC-MRM.
    Huang Y; Mou S; Wang Y; Mu R; Liang M; Rosenbaum AI
    Anal Chem; 2021 Apr; 93(15):6135-6144. PubMed ID: 33835773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of free and total target measurements as target engagement and efficacy biomarkers in biotherapeutic development--opportunities and challenges.
    Zheng S; McIntosh T; Wang W
    J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S75-84. PubMed ID: 25707966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (Part 3 - LBA, biomarkers and immunogenicity).
    Richards S; Amaravadi L; Pillutla R; Birnboeck H; Torri A; Cowan KJ; Papadimitriou A; Garofolo F; Satterwhite C; Piccoli S; Wu B; Krinos-Fiorotti C; Allinson J; Berisha F; Cocea L; Croft S; Fraser S; Galliccia F; Gorovits B; Gupta S; Gupta V; Haidar S; Hottenstein C; Ishii-Watabe A; Jani D; Kadavil J; Kamerud J; Kramer D; Litwin V; Lima Santos GM; Nelson R; Ni Y; Pedras-Vasconcelos J; Qiu Y; Rhyne P; Safavi A; Saito Y; Savoie N; Scheibner K; Schick E; Siguenza PY; Smeraglia J; Staack RF; Subramanyam M; Sumner G; Thway T; Uhlinger D; Ullmann M; Vitaliti A; Welink J; Whiting CC; Xue L; Zeng R
    Bioanalysis; 2016 Dec; 8(23):2475-2496. PubMed ID: 27855512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioanalysis of target biomarker and PK/PD relevancy during the development of biotherapeutics.
    Lee JW; Salimi-Moosavi H
    Bioanalysis; 2012 Oct; 4(20):2513-23. PubMed ID: 23157359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics.
    Kaur S; Xu K; Saad OM; Dere RC; Carrasco-Triguero M
    Bioanalysis; 2013 Jan; 5(2):201-26. PubMed ID: 23330562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioanalytical platform comparison using a generic human IgG PK assay format.
    Leary BA; Lawrence-Henderson R; Mallozzi C; Fernandez Ocaña M; Duriga N; O'Hara DM; Kavosi M; Qu Q; Joyce AP
    J Immunol Methods; 2013 Nov; 397(1-2):28-36. PubMed ID: 23994108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement of Free Versus Total Therapeutic Monoclonal Antibody in Pharmacokinetic Assessment is Modulated by Affinity, Incubation Time, and Bioanalytical Platform.
    Talbot JJ; Calamba D; Pai M; Ma M; Thway TM
    AAPS J; 2015 Nov; 17(6):1446-54. PubMed ID: 26265093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2017 White Paper on recent issues in bioanalysis: a global perspective on immunogenicity guidelines & biomarker assay performance (Part 3 - LBA: immunogenicity, biomarkers and PK assays).
    Gupta S; Richards S; Amaravadi L; Piccoli S; Desilva B; Pillutla R; Stevenson L; Mehta D; Carrasco-Triguero M; Neely R; Partridge M; Staack RF; Zhao X; Gorovits B; Kolaitis G; Sumner G; Stubenrauch KG; Zou L; Amur S; Beaver C; Berger I; Berisha F; Birnboeck H; Bower J; Cho SJ; Cludts I; Cocea L; Donato LD; Fischer S; Fraser S; Garofolo F; Haidar S; Haulenbeek J; Hottenstein C; Hu J; Ishii-Watabe A; Islam R; Jani D; Kadavil J; Kamerud J; Kramer D; Kurki P; MacMannis S; McNally J; Mullan A; Papadimitriou A; Pedras-Vasconcelos J; Ray S; Safavi A; Saito Y; Savoie N; Fjording MS; Scheibner K; Smeraglia J; Song A; Stouffer B; Tampal N; der Strate BV; Verch T; Welink J; Xu Y; Yang TY; Yengi L; Zeng J; Zhang Y; Zhang Y; Zoog S
    Bioanalysis; 2017 Dec; 9(24):1967-1996. PubMed ID: 29205064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets.
    Davda JP; Hansen RJ
    MAbs; 2010; 2(5):576-88. PubMed ID: 20676036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Target-mediated drug disposition model for drugs that bind to more than one target.
    Gibiansky L; Gibiansky E
    J Pharmacokinet Pharmacodyn; 2010 Aug; 37(4):323-46. PubMed ID: 20669044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty.
    Mager DE; Mascelli MA; Kleiman NS; Fitzgerald DJ; Abernethy DR
    J Pharmacol Exp Ther; 2003 Dec; 307(3):969-76. PubMed ID: 14534354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ADME Considerations and Bioanalytical Strategies for Pharmacokinetic Assessments of Antibody-Drug Conjugates.
    Mou S; Huang Y; Rosenbaum AI
    Antibodies (Basel); 2018 Nov; 7(4):. PubMed ID: 31544891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two validated liquid chromatography-mass spectrometry methods with different pretreatments for the quantification of an anti-CD47 monoclonal antibody in rat and cynomolgus monkey serum compared with an electrochemiluminescence method.
    Gao Y; Zhang D; Yang C; Duan X; Li X; Zhong D
    J Pharm Biomed Anal; 2019 Oct; 175():112792. PubMed ID: 31377653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.